Primary human glioblastomas - prognostic value of clinical and histopathological parameters

Clinical Neuropathology

Volumn 31, Issue 5, 2012, Pages 361-368

  Habberstad, Andreas H ^a   Lind Landström, Tove ^a   Sundstrøm, Stein ^b   Torp, Sverre H ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain neoplasm; Classification; Diagnosis; Gliomas; Necrosis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CALCIFICATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MITOSIS; NECROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOSIS;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84867598511     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300439     Document Type: Article

References (33)

1. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, Von Deimling A, Ohgaki H, Cavenee W. K. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumours of the central nervous system 4edn. Lyon: International Agency for Research on Cancer (IACC); 2007. p. 33-49.
2. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010; 122: 159-167. doi:10.111 1/j.1600-04 04.2010.01350.x PubMed
3. Theeler BJ, Groves MD. High-grade gliomas. Curr Treat Options Neurol. 2011; 13: 386-399. doi:10.1007/s11940-011-0130-0 PubMed
4. Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011; 70: 101-109. doi:10.1097/NEN.0b0 13e31 82 0 681aa PubMed
5. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988; 62: 2152-2165. doi:10.1002/1097-0142(19881115)62:10 < 2152:AID-CNCR2820621015 > 3.0.CO;2-T PubMed
6. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987; 59: 1617-1625. doi:10.1002/1097-0142(19870501)59:9 < 161 7::AI D-CNCR2820590916 > 3.0.CO;2-X PubMed
7. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidi vous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg. 1978; 49: 854-861. doi:10.3171/jns.1978. 49.6. 08 54 PubMed
8. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. 1999; 1: 44-51. PubMed
9. Homma TT, Fukushima TT, Vaccarella SS, Yonekawa YY, Di Patre PLP, Franceschi SS, Ohgaki HH. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006; 65: 846-854. doi:10.1097/01. jnen.0000235118.75182.94 PubMed
10. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004; 101: 2318-2326. doi:10.1002/cncr.20625 PubMed
11. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med. 2007; 131: 397-406. PubMed
12. Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, Giangaspero F, Delfini R, Santoro A. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol. 2009; 94: 129-134. doi:10.1007/s11060-009-9815-6 PubMed
13. WHO handbook for reporting results of cancer treatment. WHO Publication no. 48. Geneva: World Health Organization; 1979.
14. StatBank Norway. Oslo: Statistics Norway; 2011; cited 2011 19.08. Available from: http://statbank. ssb.no/statistikkbanken/Default_FR.asp?PXSid = 0&nvl = true&PLanguage = 1&tilside = selecttable/ hovedtabellHjem.asp&KortnavnWeb = folkendrhist.
15. Ohgaki HH. Genetic pathways to glioblastomas. Neuropathology. 2005; 25: 1-7. doi:10.1111/j.1 440-1789.2004.00600.x PubMed
16. Burger PC, Vollmer RT. Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer. 1980; 46: 1179-1186. doi:1 0.1002/1097-0142(19800901)46:5 < 117 9::A IDCNCR2820460517 > 3.0.CO;2-0 PubMed
17. Scheithauer BW, Fuller GN, VandenBerg SR. The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol. 2008; 18: 307-316. doi:10.11 11/j.1750-3639.2008.00179.x PubMed
18. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006; 1: 97-117. doi:10.1146/annurev.pathol.1.110304.100043 PubMed
19. Schiffer D. Classification and biology of astrocytic gliomas. Forum (Genova). 1998; 8: 244-255. PubMed
20. Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009; 16: 1119-1130. doi:10.1016/j. jocn.2009.02.009 PubMed
21. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008; 113: 1032-1042. doi:10.1002/cncr.23678 PubMed
22. Scherer HJ. Structural development in gliomas. Am J Cancer. 1938; 34: 333-351.
23. Laws ER Jr, Goldberg WJ, Bernstein JJ. Migration of human malignant astrocytoma cells in the mammalian brain: Scherer revisited. Int J Dev Neurosci. 1993; 11: 691-697. doi:10.1016/0736-5748(93)90056-J PubMed
24. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002; 12: 108-116. doi:10.1111/j.1750-3639.2002.tb00427.x PubMed
25. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003; 63: 1602-1607. PubMed
26. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985; 56: 1106-1111. doi:10.1002/1097-0142(19850901)56:5 < 1106::AID-CNCR2820 56 0 525 > 3.0.CO;2-2 PubMed
27. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol. 2010; 2010.
28. Khan-Farooqi HR, Prins RM, Liau LM. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res. 2005; 27: 692-702. doi:10.1 179 /01 6164105X49490 PubMed
29. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109. doi:10.1007/s00401-007-0243-4 PubMed
30. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P. Which glioblastoma multiforme patient will become a long-term survivor? A populationbased study. Ann Neurol. 1999; 46: 183-188. doi:10.1002/1531-8249(199908)46:2 < 183::AI D- A NA7 > 3.0.CO;2-7 PubMed
31. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004; 101: 219-226. doi:10.3171/jns.2004.101.2.0219 PubMed
32. Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berweiler U, Roggendorf W, Diete S, Dietzmann K, Müller B, Heuser K, Reifenberger G, Schlegel U. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol. 2000; 247: 455-460. doi:10.1007/s004150070175 PubMed
33. Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M, Sanson M. Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther. 2011; 11: 781-789. doi:10.1586/era.10.202 PubMed